Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LENZ Therapeutics, Inc.LENZ · Entity 6475 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LENZ Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.63 · Expires 2036-06-15 | Direct | 22,100 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 22,100 · Balance 22,100 F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 00:18 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 22,100 | $0.00 Strike: $6.63 | $0.00 |
DisclosureSEC source: 0001200889-26-000001 · wk-form4_1781569089.xml · derivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2036-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:13 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | PurchaseCommon Stock | 10,500 | $22.79 | $239,278.20 |
DisclosureSEC source: 0001815776-25-000073 · wk-form4_1762809230.xml · nonDerivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 F1 · price: Represents the weighted average share price of an aggregate total of 10,500 shares purchased in the price range of $22.68 to $22.87 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000044 · wk-form4_1749678354.xml · derivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| May 13, 2024 Filed May 14, 2024 21:29 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | PurchaseCommon Stock | 31,332 | $15.99 | $501,092.68 |
DisclosureSEC source: 0001815776-24-000044 · wk-form4_1715722170.xml · nonDerivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 525,565 F1 · price: Represents the weighted average share price of an aggregate total of 31,332 shares purchased in the price range of $15.96 to $16.00 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · derivative · entry 5 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-03-20 F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantWarrant (right to buy) · Derivative | 6,575 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · derivative · entry 4 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 6,575 Underlying: Common Stock · 6,575 shares Expires 2027-10-30 F3 · date: Warrant assumed in connection with the closing of the transactions contemplated by the Merger Agreement, in exchange of an outstanding warrant to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantCommon Stock | 16,633 | $15.03 | $249,992.33 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · nonDerivative · entry 3 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 494,233 F2 · shares: Shares issued upon the closing of the private placement financing under the Subscription Agreement by and among the Issuer, the Reporting Person and the other purchasers party thereto, dated as of November 14, 2023, pursuant to which, immediately following the closing of the transactions contemplated by the Merger Agreement, such purchasers purchased an aggregate of 3,559,565 shares of Common Stock at a price of $15.0299 per share for aggregate gross proceeds to the Issuer of approximately $53.5 million, as more fully described in the Issuer's reports filed with the Securities and Exchange Commission. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantCommon Stock | 477,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · nonDerivative · entry 2 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 477,600 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantCommon Stock | 95,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · nonDerivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,034 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.